The strategy is safe and slows the worsening of several nonmotor symptoms.
Depression and cognitive impairment are common neuropsychiatric symptoms in patients with Parkinson disease (PD). In a reanalysis of a manufacturer-funded and -conducted study (N=1174 patients with early untreated PD), researchers examined whether adding rasagiline, a selective monoamine oxidase (MAO) B inhibitor, to antidepressant pharmacotherapy affects the progression of nonmotor PD symptoms and is safe.
The current analysis involved a subgroup of 191 patients who were receiving antidepressants (selective serotonin reuptake inhibitors, 76.0%; tricyclic antidepressants, 21.4%; serotonin-norepinephrine reuptake inhibitors, 0.5%; other, 8.3%). Patients with major depression were excluded. Ratings of depression, cognition, daytime sleepiness,…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)